Dr. Michael Ropacki is the President of a San Francisco based consultancy firm, Strategic Global Research & Development (SGR&D) that collaborates with sponsors developing and executing Clinical Development Plans to optimize regulatory interactions. Prior to his role at SGR&D, Dr. Ropacki was most recently Senior Vice President of Clinical Development at MedAvante-ProPhase. Before that, Dr. Ropacki held roles of increasing responsibility at Johnson & Johnson (NYSE: JNJ), his last as Director of Clinical Development, Neuroscience, Research and Development, for Janssen Research & Development, serving as the Clinical Lead responsible for developing and leading the Cognitive Health in Aging Registry. Prior to that role, Dr. Ropacki served as Global Medical Affairs Leader, Head of Late-Stage Development at Janssen Alzheimer’s Immunotherapy, LLC. Dr. Ropacki is also Co-Chair of a Scientific Advisory Group for the Innovative Medicines Initiative-European Prevention of Alzheimer’s Dementia (IMI-EPAD) program and as a National Institute of Health (NIH) advisor. He holds a doctorate from Texas Tech University. He completed his internship/residency at University of Oklahoma Health Sciences Center in Psychiatry and two post-doctoral fellowships at Brown University School of Medicine and UCLA School of Medicine, Neuropsychiatric Institute.